SG10201602569RA - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety - Google Patents

Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Info

Publication number
SG10201602569RA
SG10201602569RA SG10201602569RA SG10201602569RA SG10201602569RA SG 10201602569R A SG10201602569R A SG 10201602569RA SG 10201602569R A SG10201602569R A SG 10201602569RA SG 10201602569R A SG10201602569R A SG 10201602569RA SG 10201602569R A SG10201602569R A SG 10201602569RA
Authority
SG
Singapore
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
SG10201602569RA
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of SG10201602569RA publication Critical patent/SG10201602569RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
SG10201602569RA 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety SG10201602569RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
SG10201602569RA true SG10201602569RA (en) 2016-05-30

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201602569RA SG10201602569RA (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
SG2013070883A SG193563A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013070883A SG193563A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Country Status (29)

Country Link
US (7) US8710219B2 (en)
EP (2) EP3111938B1 (en)
JP (3) JP6242331B2 (en)
KR (2) KR101902325B1 (en)
CN (2) CN103582483B (en)
AU (1) AU2012236367B2 (en)
CA (1) CA2830822C (en)
CL (1) CL2013002823A1 (en)
CY (2) CY1117785T1 (en)
DK (2) DK2694075T3 (en)
EA (1) EA022434B9 (en)
ES (2) ES2577982T3 (en)
HK (1) HK1194969A1 (en)
HR (2) HRP20160545T1 (en)
HU (2) HUE028910T2 (en)
IL (2) IL228588A (en)
LT (1) LT3111938T (en)
ME (2) ME03523B (en)
MX (1) MX340577B (en)
PE (1) PE20141382A1 (en)
PL (2) PL2694075T3 (en)
PT (2) PT3111938T (en)
RS (2) RS59219B1 (en)
SG (2) SG10201602569RA (en)
SI (2) SI3111938T1 (en)
SM (1) SMT201600179B (en)
TW (1) TWI571469B (en)
WO (1) WO2012135571A1 (en)
ZA (2) ZA201307082B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI558710B (en) 2009-01-08 2016-11-21 古利斯股份有限公司 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
SG10201602569RA (en) 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AR088872A1 (en) 2011-11-14 2014-07-16 Cephalon Inc URACILO DERIVATIVES AS INHIBITORS OF THE AXL AND C-MET KINASE
CN104725301A (en) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 Preparation method of 1,2-dihydropyridin-2-one derivative
ES2833473T3 (en) * 2015-04-21 2021-06-15 Chengdu Zenitar Biomedical Tech Co Ltd Purinyl-N-hydroxyl pyrimidine formamide derivatives, method of preparation and use thereof
CA3030660C (en) * 2016-07-19 2023-01-17 National Institute Of Plant Genome Research Mutated protein from burkholderia gladioli strain ngj1 against fungal pathogens
BR112019008698A2 (en) * 2016-11-02 2019-07-16 Curis Inc method for treating cancer in a subject who needs it and pharmaceutical composition
CA3081815A1 (en) * 2017-11-06 2019-05-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
CN113164466A (en) 2018-09-11 2021-07-23 柯瑞斯公司 Combination therapy using phosphoinositide 3-kinase inhibitors having zinc binding moieties
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
DE60144322D1 (en) 2000-04-27 2011-05-12 Astellas Pharma Inc CONDENSED HETEROARYL DERIVATIVES
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2476296C (en) 2002-03-13 2011-02-22 Janssen Pharmaceutica N.V. Amino-derivatives as inhibitors of histone deacetylase
AU2003212336B2 (en) 2002-03-13 2008-12-18 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
PL214279B1 (en) 2002-03-13 2013-07-31 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
KR20040090978A (en) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CN101153042A (en) 2003-01-29 2008-04-02 武田药品工业株式会社 Thienopyrimidine compound and use of the same
EP1745022B1 (en) * 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc Aromatic-ring-fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2006082428A2 (en) 2005-02-03 2006-08-10 Topotarget Uk Limited Combination therapies using hdac inhibitors
ES2553178T3 (en) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Substituted derivatives of aminopropenyl piperidine or morpholine as new histone deacetylase inhibitors
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AR060632A1 (en) 2006-04-26 2008-07-02 Genentech Inc PHOSFOINOSITIDE INHIBITING COMPOUNDS 3- KINASE AND METHODS OF USE
WO2007127175A2 (en) * 2006-04-26 2007-11-08 F. Hoffmann-La Roche Ag Pharmaceutical compounds
CL2007001165A1 (en) 2006-04-26 2008-01-25 Hoffmann La Roche 2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases.
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7888361B2 (en) 2006-09-11 2011-02-15 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
CA2662617C (en) 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
RU2470936C2 (en) 2006-12-07 2012-12-27 Дженентек, Инк. Phosphoinositide3-kinase inhibiting compounds and methods for use thereof
CA2671782C (en) * 2006-12-07 2017-01-10 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
US20080234332A1 (en) 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
PE20140100A1 (en) 2007-09-12 2014-02-12 Genentech Inc COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITING COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909631B (en) * 2007-10-25 2012-09-12 健泰科生物技术公司 Process for making thienopyrimidine compounds
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
JP2011525535A (en) 2008-06-24 2011-09-22 武田薬品工業株式会社 PI3K / mTOR inhibitor
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
TWI558710B (en) * 2009-01-08 2016-11-21 古利斯股份有限公司 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX2011009167A (en) 2009-03-12 2011-09-15 Genentech Inc Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies.
KR101489045B1 (en) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Combinations of a pi3k inhibitor and a mek inhibitor
CN102970868A (en) 2010-04-16 2013-03-13 柯瑞斯公司 Treatment of cancers having K-RAS mutations
SG10201602569RA (en) * 2011-04-01 2016-05-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
JP6238459B2 (en) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Method for treating cancer using PD-1 axis binding antagonist and MEK inhibitor
CA2983597A1 (en) 2015-06-25 2016-12-29 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
BR112019008698A2 (en) * 2016-11-02 2019-07-16 Curis Inc method for treating cancer in a subject who needs it and pharmaceutical composition

Also Published As

Publication number Publication date
US9249156B2 (en) 2016-02-02
US20170304279A1 (en) 2017-10-26
CA2830822C (en) 2018-10-02
US20130090335A1 (en) 2013-04-11
BR112013025340A2 (en) 2016-12-13
US10543197B2 (en) 2020-01-28
IL248597A0 (en) 2016-12-29
PT2694075T (en) 2016-07-11
US20140243330A1 (en) 2014-08-28
RS54903B1 (en) 2016-10-31
US9657032B2 (en) 2017-05-23
PL2694075T3 (en) 2016-09-30
ZA201406167B (en) 2015-03-25
LT3111938T (en) 2019-06-25
ES2577982T3 (en) 2016-07-19
DK3111938T3 (en) 2019-07-01
KR101902325B1 (en) 2018-09-28
SG193563A1 (en) 2013-11-29
US10111864B2 (en) 2018-10-30
CY1117785T1 (en) 2017-05-17
ME02451B (en) 2016-09-20
HRP20160545T1 (en) 2016-06-17
CY1121825T1 (en) 2020-07-31
HRP20191091T1 (en) 2019-09-20
EA201301114A1 (en) 2014-04-30
AU2012236367B2 (en) 2014-10-09
RS59219B1 (en) 2019-10-31
KR20180108848A (en) 2018-10-04
US20220168284A1 (en) 2022-06-02
US11135205B2 (en) 2021-10-05
MX340577B (en) 2016-07-13
MX2013011132A (en) 2014-03-12
SI3111938T1 (en) 2019-08-30
PL3111938T3 (en) 2019-09-30
JP2018052987A (en) 2018-04-05
HUE028910T2 (en) 2017-01-30
HUE045041T2 (en) 2019-12-30
CA2830822A1 (en) 2012-10-04
PE20141382A1 (en) 2014-11-04
TW201247678A (en) 2012-12-01
SI2694075T1 (en) 2016-07-29
PT3111938T (en) 2019-07-10
US11654136B2 (en) 2023-05-23
IL248597B (en) 2018-04-30
IL228588A0 (en) 2013-12-31
NZ615586A (en) 2015-02-27
HK1194969A1 (en) 2014-10-31
EP2694075A4 (en) 2014-10-01
EP3111938B1 (en) 2019-05-08
JP2014509653A (en) 2014-04-21
TWI571469B (en) 2017-02-21
US20200215039A1 (en) 2020-07-09
ZA201307082B (en) 2015-04-29
CL2013002823A1 (en) 2014-04-11
US20190091211A1 (en) 2019-03-28
NZ705039A (en) 2016-03-31
ME03523B (en) 2020-04-20
EA022434B1 (en) 2015-12-30
EP3111938A1 (en) 2017-01-04
KR20140023333A (en) 2014-02-26
ES2733128T3 (en) 2019-11-27
WO2012135571A1 (en) 2012-10-04
US20160185796A1 (en) 2016-06-30
CN103582483A (en) 2014-02-12
CN105461736A (en) 2016-04-06
SMT201600179B (en) 2016-08-31
AU2012236367A1 (en) 2013-04-18
JP2016188255A (en) 2016-11-04
DK2694075T3 (en) 2016-08-01
CN105461736B (en) 2018-06-12
EP2694075A1 (en) 2014-02-12
EP2694075B1 (en) 2016-04-27
JP6275784B2 (en) 2018-02-07
US8710219B2 (en) 2014-04-29
IL228588A (en) 2016-11-30
EA022434B9 (en) 2016-02-29
JP6242331B2 (en) 2017-12-06
CN103582483B (en) 2016-02-17

Similar Documents

Publication Publication Date Title
IL237727A0 (en) Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
IL248597B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
HK1258842A1 (en) A composition for detecting biofilms on viable tissues
GB2481513B (en) A magazine add-on
ZA201306639B (en) Attachment mechanism for a contaienr
EP2611352A4 (en) A dishwahser
EP2696949A4 (en) A binding
GB2484514B (en) A mechanism
GB201200412D0 (en) A rake
AU332323S (en) A bumper guard
AU332267S (en) A bumper guard
GB201013994D0 (en) A camrea accessory
GB201116046D0 (en) A cover
GB201010041D0 (en) Drawer assembly for a vehicle
GB201116008D0 (en) A kennel